I agree with $1 possibly by end of 2021 but the company has stated they will partner with pharma and I guess they don't want to bring to market themselves. the size of the market is huge and so pharma will have to pay up for the IP and a bidding war would be ideal for the big pharma who want to combine NYR drug with their statin. this would improve patent lifespan too.
there is a lot of news expected this quarter. 1. further safety data from December study. 2. new 6-8 week study combining nyr drug and statin in vivo (standard mouse model).
these will hopefully show efficacy and safety and give the green light for human studies later this year.
the prospectus says if share price greater than 40c for five days or more and drug is recommended for human trials there is a bonus for directors.
so expecting big things this year.
NYR Price at posting:
31.5¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)